Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial

Mengqiu Gao, Jingtao Gao, Jian Du, Yuhong Liu, Yao Zhang, Liping Ma, Fengling Mi, Liang Li, Shenjie Tang, Trial Team, Tang Shenjie, Li Liang, Gao Mengqiu, Liu Yuhong, Zhang Yao, Du Jian, Gao Jingtao, Ma Liping, Liu Rongmei, Ma Yan, Ding Xiaofen, Zhong Li, Xiao Hua, Shu Wei, Lv Zizheng, Guo Zhenyong, Wang Hong, Xie Shiheng, Mengqiu Gao, Jingtao Gao, Jian Du, Yuhong Liu, Yao Zhang, Liping Ma, Fengling Mi, Liang Li, Shenjie Tang, Trial Team, Tang Shenjie, Li Liang, Gao Mengqiu, Liu Yuhong, Zhang Yao, Du Jian, Gao Jingtao, Ma Liping, Liu Rongmei, Ma Yan, Ding Xiaofen, Zhong Li, Xiao Hua, Shu Wei, Lv Zizheng, Guo Zhenyong, Wang Hong, Xie Shiheng

Abstract

Background: Shortening the standard 6-month treatment for drug-susceptible pulmonary tuberculosis (DS-PTB) would be a major improvement for TB case management and disease control.

Methods: We are conducting a randomized, open-label, controlled, non-inferiority trial involving patients with smear-positive, newly diagnosed DS-PTB cases nationwide to assess the efficacy and safety of two 4.5- month regimens in comparison to the standard 6-month WHO recommended regimen. The regimen used in one experiment group is a 4.5-month fluoroquinolone-containing regimen, which consists of full course of levofloxacin, isoniazid (H), rifampin (R), parazinamid (Z) and ethambutol (E). Regimen used in the second experiment group includes 4.5-month full course of H, R, Z, E with levofloxacin removed. Patients in the control group, receive H, R, Z and E for 2 months, followed by 4 months of H and R. The primary endpoint is treatment failure or relapse within 24 month after treatment completion.

Discussion: Results from this trial along with other studies will contribute to the science of constructing a shorter, effective and safe regiment for TB patients.

Trial registration: The protocol has been registered on ClinicalTrials.gov on 2 September,2016 with identifier NCT02901288 .

Keywords: Clinical trial; Drug susceptible pulmonary tuberculosis; Short course chemotherapy.

References

    1. World Health Organization . Global tuberculosis report 2016. Geneva: WHO; 2016.
    1. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601. doi: 10.1371/journal.pone.0017601.
    1. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(3):852–857. doi: 10.1128/AAC.01036-07.
    1. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone-mediated bacterial death. Antimicrob Agents Chemother. 2008;52(2):385–392. doi: 10.1128/AAC.01617-06.
    1. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloguin CA, Elsenach KD, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10(6):605–612.
    1. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2002;20(6):464–467. doi: 10.1016/S0924-8579(02)00239-X.
    1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587. doi: 10.1056/NEJMoa1407426.
    1. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–1598. doi: 10.1056/NEJMoa1315817.
    1. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–1608. doi: 10.1056/NEJMoa1314210.
    1. Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother. 2011;55(12):5421–5429. doi: 10.1128/AAC.00695-11.
    1. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12(2):128–138.
    1. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, 3rd, et al. Pyrazinamade inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi: 10.1126/science.1208813.
    1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–S279.
    1. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353. doi: 10.1186/1745-6215-15-353.
    1. Van Denu A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–692. doi: 10.1164/rccm.201001-0077OC.
    1. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful “9-month Bangladesh regimen” for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180–1187. doi: 10.5588/ijtld.14.0100.
    1. East African/British Medical Research Council Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;1(7760):1079–1085.
    1. East African/British Medical Research Council Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for the treatment of pulmonary tuberculosis. Lancet. 1974;2(7889):1100–1106.
    1. East African/British Medical Research Council Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1977;116(1):3–8.
    1. East African/British Medical Research Council Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis. 1978;118(1):39–48.
    1. East African/British Medical Research Councils Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: Second report of the 4th study. Am Rev Respir Dis. 1981;123(2):165–170.
    1. East African/British Medical Research Council Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report. Lancet. 1978;2(8085):334–338.
    1. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Doman SE, Booth J, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003;37(11):1448–1452. doi: 10.1086/379328.
    1. Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Lew WJ, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis. 2007;11(3):319–324.
    1. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007;59(5):860–865. doi: 10.1093/jac/dkm061.
    1. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61(10):903–908. doi: 10.1136/thx.2005.056887.
    1. Wang Y, Xiao DL, Wang WJ, Liu X, Wang LX, Xu SF, et al. The fifth national epidemiological survey across China 2010. Beijing: Press of Military Medical Sciences; 2011. p. 169401.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する